

Corporate Headquarters

SHANDONG WEIGAO BLOOD PURIFICATION PRODUCTS CO., LTD. Tel: +86 631 5660598 Fax: +86 631 5660598

International Business Headquarters

WEGO HEALTHCARE (SHENZHEN) CO., LTD.

19F, Building 3, Sunmax Technology Plaza, No.8 Keyuan Road, Nanshan District, Shenzhen, China Tel: +86 755 33892500 Fax:+86 755 33892508 E-mail: info@wego-healthcare.com www.wego-healthcare.com/en **EH** series


Hollow Fiber Dialyzer


Electron Beam Sterilization



1 High-Flux dialysis membranes improve the patients' survival probability


- European multi-center MPO study shows that high-flux dialysis membranes can significantly improve patients' survival probability with a serum albumin levels ≤4g/dL.
- High-Flux dialysis membranes improve the patients' survival probability with diabetic nephropathy.





2 High-Flux dialysis membranes improve the patients' prognosis


The results of famous HEMO study reveals that the all-cause mortality risk of high-flux dialysis membranes for the patients with dialysis duration over 3.7 years is 0.68, which has decreased to 32%.



3 WEGO 3rd generation nano-spinning technology


WEGO 3rd generation membrane nano-spinning technology makes the membrane pores smoother and effectively reduces the resistance of transmembrane movement of middle and large molecules.

This innovative technology enables higher porosity on the inner surface of the membrane and increases the contact surface for substances exchange, facilitating better HDF therapy.




Better removal of small-large molecule endotoxins


Continuous technical upgrades enable the products to have better ultrafiltration coefficients.



5 Better removal of medium-large molecule endotoxins

The optimized design of the hollow fiber membrane enables the product to have a better removal of medium-large molecule endotoxin.





Experimental group

A randomized, parallel positive-controlled, non-inferiority trial including 216 subjects who were randomly divided into Experimental group (EH series) and control group in a 1:1 ratio was carried out to evaluate the efficacy and safety of the test product.

Technical Specification

In Vitro Performance	E15H	E16H	E17H	E18H	E19H	E20H	E21H	E22H	E23H	
	LISII	LIOII	LITTI	LIOII	LISII	LZUII	LZIII	LZZII	LZJII	
Ultrafiltration coefficient (mL/h • mmHg)	61	64	67	69	72	73	75	79	84	
Clearance (Q _B =200ml/min)										
Urea	198	198	198	198	199	199	200	200	200	
Creatinine	196	196	197	197	198	198	198	198	198	
Phosphate	185	186	189	189	194	196	196	197	198	
Vitamin B ₁₂	143	146	149	152	156	161	167	173	178	
Clearance (QB=300ml/min)										
Urea	272	273	275	280	282	288	289	290	292	
Creatinine	254	257	263	270	275	279	280	282	285	
Phosphate	238	242	250	255	268	274	277	279	281	
Vitamin B ₁₂	159	165	170	176	181	189	198	206	209	
Clearance (QB=400ml/mir	n)									
Urea	333	336	339	343	349	352	355	360	365	
Creatinine	297	302	308	313	319	322	327	331	334	
Phosphate	287	293	300	306	313	319	327	330	332	
Vitamin B ₁₂	177	183	190	196	203	206	213	221	228	
Sieving coefficient										
β2-MG	0.85									
Myohemoglobin					0.35					
Inluin					0.95					
Albumin					≤0.003					
KoA urea (mL/min)	1190	1214	1265	1415	1488	1771	1832	1900	2061	
Surface (m²)	1.5	1.6	1.7	1.8	1.9	2.0	2.1	2.2	2.3	
Priming volume (mL) bloodside	75	81	89	92	95	110	116	120	122	
Wall thickness/ Internal diameter (μm)		40/200								
Membrane material		Polysulfone								
Sterilization		Electron beam sterilization								
Units per box		24pcs/carton								

Test conditions:

Clearance in vitro: QD=500mL/min; QF=0mL/min; T=37°C

UF coefficient: Bovine plasma, QB=300mL/min; protein content: 60±5g/L; TMP=100mmHg , KoA (Qb=300mL/min)

Note: Products of this series have high performance of ultrafiltration and permeability. Please use only with dialysis equipment with ultrafiltration control function.